ASCO GI 2021 | Niraparib in BAP1 and DDR pathway deficient solid tumors

Brian H. Ramnaraign, MD, University of Florida College of Medicine, Gainesville, FL, discusses the rationale of an ongoing Phase II trial investigating the PARP inhibitor, niraparib, in BRCA-1 associated Protein 1 (BAP1) and other DNA damage response (DDR) pathway deficient neoplasms, including patients with cholangiocarcinoma. This interview was recorded via an online conference call with The Video Journal of Oncology (VJOncology).